Literature DB >> 23801162

[Uropathology - requirements for standards and quality].

C Wittekind1, A Karl.   

Abstract

The variety of therapeutic approaches to urological diseases, particularly in urological oncology increases the need for detailed and standardized uropathological diagnostic procedures. A standardized diagnostic approach helps to achieve a high quality of diagnoses in uropathology. It is now expected that certain features in biopsies and resected tumors will be evaluated and described in pathology reports. German pathology offers guidelines for handling specimens and in addition there are some sophisticated clinical/pathological guidelines (e.g. European guidelines) with specific standards relating to diagnostic requirements which will be discussed in this article. There are German pathology guidelines for tumors of the prostate, testis, kidneys, renal pelvis, urethra and urinary bladder.

Entities:  

Mesh:

Year:  2013        PMID: 23801162     DOI: 10.1007/s00120-013-3226-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  2 in total

1.  Practice protocol for the examination of specimens removed from patients with carcinoma of the urinary bladder, ureter, renal pelvis, and urethra.

Authors:  E H Hammond; D E Henson
Journal:  Arch Pathol Lab Med       Date:  1996-12       Impact factor: 5.534

2.  Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.

Authors:  J Beyer; P Albers; R Altena; J Aparicio; C Bokemeyer; J Busch; R Cathomas; E Cavallin-Stahl; N W Clarke; J Claßen; G Cohn-Cedermark; A A Dahl; G Daugaard; U De Giorgi; M De Santis; M De Wit; R De Wit; K P Dieckmann; M Fenner; K Fizazi; A Flechon; S D Fossa; J R Germá Lluch; J A Gietema; S Gillessen; A Giwercman; J T Hartmann; A Heidenreich; M Hentrich; F Honecker; A Horwich; R A Huddart; S Kliesch; C Kollmannsberger; S Krege; M P Laguna; L H J Looijenga; A Lorch; J P Lotz; F Mayer; A Necchi; N Nicolai; J Nuver; K Oechsle; J Oldenburg; J W Oosterhuis; T Powles; E Rajpert-De Meyts; O Rick; G Rosti; R Salvioni; M Schrader; S Schweyer; F Sedlmayer; A Sohaib; R Souchon; T Tandstad; C Winter; C Wittekind
Journal:  Ann Oncol       Date:  2012-11-14       Impact factor: 32.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.